Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Trends in Biotechnology
|
August 30, 2025
Extended human lymph node explants for evaluation of adaptive immunity
Kanishka Fernando, Hong Sheng Quah, Lisda Suteja, et al.
Cancer Immunology, Immunotherapy : CII
|
September 28, 2021
Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures
Yvonne H F Teng, Hong Sheng Quah, Lisda Suteja, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 11, 2021
Intratumoral CD39<sup>+</sup>CD8<sup>+</sup> T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC
Joe Yeong, Lisda Suteja, Yannick Simoni, et al.
Cancers
|
April 26, 2020
Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy
Wai Nam Liu, Shin Yie Fong, Wilson Wei Sheng Tan, et al.
Science Advances
|
November 23, 2022
Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model
Wai Nam Liu, Wing Yan So, Sarah L Harden, et al.
Nature Communications
|
March 27, 2023
Single cell analysis in head and neck cancer reveals potential immune evasion mechanisms during early metastasis
Hong Sheng Quah, Elaine Yiqun Cao, Lisda Suteja, et al.
Nature Communications
|
May 15, 2023
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
Darren Wan-Teck Lim, Hsiang-Fong Kao, Lisda Suteja, et al.
JTO Clinical and Research Reports
|
November 25, 2022
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
Gillianne G Y Lai, Jia Chi Yeo, Amit Jain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2021
Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
Khi Pin Chua, Yvonne H F Teng, Aaron C Tan, et al.
Nature Genetics
|
February 5, 2020
Genomic landscape of lung adenocarcinoma in East Asians
Jianbin Chen, Hechuan Yang, Audrey Su Min Teo, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Trends in Biotechnology
|
August 30, 2025
Extended human lymph node explants for evaluation of adaptive immunity
Kanishka Fernando, Hong Sheng Quah, Lisda Suteja, et al.
Cancer Immunology, Immunotherapy : CII
|
September 28, 2021
Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures
Yvonne H F Teng, Hong Sheng Quah, Lisda Suteja, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 11, 2021
Intratumoral CD39<sup>+</sup>CD8<sup>+</sup> T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC
Joe Yeong, Lisda Suteja, Yannick Simoni, et al.
Cancers
|
April 26, 2020
Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy
Wai Nam Liu, Shin Yie Fong, Wilson Wei Sheng Tan, et al.
Science Advances
|
November 23, 2022
Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model
Wai Nam Liu, Wing Yan So, Sarah L Harden, et al.
Nature Communications
|
March 27, 2023
Single cell analysis in head and neck cancer reveals potential immune evasion mechanisms during early metastasis
Hong Sheng Quah, Elaine Yiqun Cao, Lisda Suteja, et al.
Nature Communications
|
May 15, 2023
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
Darren Wan-Teck Lim, Hsiang-Fong Kao, Lisda Suteja, et al.
JTO Clinical and Research Reports
|
November 25, 2022
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
Gillianne G Y Lai, Jia Chi Yeo, Amit Jain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2021
Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
Khi Pin Chua, Yvonne H F Teng, Aaron C Tan, et al.
Nature Genetics
|
February 5, 2020
Genomic landscape of lung adenocarcinoma in East Asians
Jianbin Chen, Hechuan Yang, Audrey Su Min Teo, et al.
Page
of 1